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Although much is known about how chromosome
segregation is coupled to cell division, how intracel-
lular organelles partition during mitotic division is
poorly understood. We report that the phosphoryla-
tion-dependent degradation of the ARFGEF GBF1
regulates organelle trafficking during cell division.
We show that, in mitosis, GBF1 is phosphorylated
on Ser292 and Ser297 by casein kinase-2 allowing
recognition by the F-box protein bTrCP. GBF1 inter-
action with bTrCP recruits GBF1 to the SCFbTrCP
ubiquitin ligase complex, triggering its degradation.
Phosphorylation and degradation of GBF1 occur
along microtubules at the intercellular bridge of
telophase cells and are required for Golgi mem-
brane positioning and postmitotic Golgi reformation.
Indeed, expression of a non-degradable GBF1
mutant inhibits the transport of the Golgi cluster
adjacent to the midbody toward the Golgi twin posi-
tioned next to the centrosome and results in defec-
tive Golgi reassembly and cytokinesis failure. These
findings define a mechanism that controls postmi-
totic Golgi reassembly and inheritance.
INTRODUCTION
During cell division, not only chromosomes need to be equally
distributed between daughter cells, but also organelles have to
be faithfully partitioned. To ensure cell viability, organelle segre-
gation must be spatially and temporally controlled and coupled
to mitotic division and cytokinesis. The mammalian Golgi appa-
ratus, which in interphase is formed by stacked cisternae linked
to form a ribbon concentrated in the pericentriolar region of the
cell, becomes fragmented and dispersed at the onset of mitosis.
Golgi ribbon unlinking and unstacking is triggered by mitotic ki-
nase-dependent phosphorylation of tethering complexes such
as the Golgi reassembly stacking proteins GRASPs and the gol-Cel
This is an open access article undgin GM130. Continuous vesicle budding of the resulting single
cisternae, and the concomitant inhibition of heterotypic and ho-
motypic Golgi fusion events, lead to the formation of small tubu-
lovesicular clusters in dynamic equilibrium with free vesicles and
tubular remnants. Subsequently, these clusters and vesicles
disperse through the cytosol or, according to others, fuse to
the endoplasmic reticulum (Shorter and Warren, 2002; Tang
and Wang, 2013). In late mitosis, the reverse process occurs
and Golgi membrane fusion, stacking, and linking result in the
reformation of the Golgi ribbon typical of interphase cells. It
has been shown that the Golgi apparatus within each daughter
cell in telophase is reassembled at two distinct locations: a
smaller cluster (referred asminor twin) forms adjacent to themid-
body and a bigger cluster (major twin) is reassembled around the
microtubule organizing center (MTOC) (Altan-Bonnet et al.,
2003; Gaietta et al., 2006; Goss and Toomre, 2008; Seemann
et al., 2002; Shima et al., 1998; Shorter and Warren, 2002). In
late cytokinesis, the minor Golgi twin positioned next to the
midbody gradually migrates to the other side of the nucleus
and coalesces with the major Golgi twin, thus forming a single
juxtanuclear Golgi ribbon (Gaietta et al., 2006). Although these
elegant high-resolution live-cell imaging techniques, combined
with electron microscopy, have revealed how the Golgi appa-
ratus reforms in late mitosis, the underlying molecular mecha-
nisms remain elusive.
The ARFGEF GBF1 (Golgi-specific Brefeldin A-resistance gua-
nine nucleotide exchange factor 1) was first identified in yeast,
where its orthologs are called Gea1 and Gea2 (Peyroche et al.,
1996). Through its catalytic domain, a 200-amino acid region
termed Sec7 domain highly conserved throughout eukaryotes,
GBF1 activates the small GTPase ARF1 (ADP-ribosylation
factor-1) by catalyzing the exchange of GDP for GTP (Donaldson
and Jackson, 2000, 2011). The loading of GTP on ARF1 triggers
the release of itsmyristoylatedN-terminal amphipatic helix, which
increases the affinity of ARF1 for membranes. ARF1-GTP and
GBF1 then recruit the heptameric coatomer complex COPI
from the cytosol to form a coated vesicle (Deng et al., 2009).
Many studies have demonstrated that the GBF1-mediated acti-
vation of ARF1 is essential for maintaining Golgi structure and
traffic through the Golgi (Donaldson and Jackson, 2011).l Reports 23, 3381–3391, June 12, 2018 ª 2018 The Authors. 3381
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
In this study, we identify GBF1 as a target of Casein Kinase-2
and the SCFbTrCP ubiquitin ligase and show that GBF1 destruc-
tion in telophase is essential for Golgi reassembly and inheri-
tance during cell division.
RESULTS
GBF1 Is Degraded in Mitosis in a Phosphorylation-
Dependent Manner
We identified GBF1 as an interactor of bTrCP using a differential
immunopurification strategy followed by mass spectrometry.
FLAG epitope-tagged bTrCP2 was expressed in HEK293T cells
and bTrCP2 immunoprecipitates were then analyzed by mass
spectrometry. As a negative control, we used FLAG epitope-
tagged bTrCP2(R447A), a mutant that lacks the ability to interact
with substrates but still associates with the core subunits of the
SCF complex Skp1 and Cul1 (D’Annibale et al., 2014; Low et al.,
2014). Twelve unique peptides corresponding to GBF1 were
recovered in wild-type bTrCP2 immunoprecipitates, but not in
the bTrCP2(R447A) pull-down (Figure S1A). To confirm the inter-
action between GBF1 and bTrCP and test its specificity, we
immunoprecipitated various FLAG epitope-tagged F-box pro-
teins containingWD40 repeats as protein-protein interaction do-
mains as well as the APC/C subunits CDH1 and CDC20 (also
containingWD40 repeats), and assessed their ability to immuno-
precipitate endogenous GBF1. As shown in Figures S1B and
S1C, bTrCP1 and bTrCP2 were the only E3 substrate receptors
that coimmunoprecipitated with endogenous GBF1. bTrCP1
and bTrCP2 are two biochemically indistinguishable paralogs
of bTrCP expressed in mammalian cells. Henceforth, we will
use the protein symbol bTrCP when referring to both. Endoge-
nous bTrCP was recovered by mass spectrometry (both bTrCP1
and bTrCP2) or immunoblotting (bTrCP1) in immunoprecipitated
HA epitope-tagged GBF1 (Figures S1D and S1E). A complex
with the endogenous GBF1 and bTrCP1 proteins was also de-
tected (Figure S1F). Moreover, bTrCP1, but not an inactive
bTrCP1(DF box) mutant, induces GBF1 ubiquitylation in vitro
(Figures S1G and S1H) and in cultured cells (Figure S1I) suggest-
ing that GBF1 is a substrate of the SCFbTrCP ubiquitin ligase.
A common feature of SCFbTrCP substrates is a phosphorylated
recognition sequence required for bTrCP binding, known as a
phosphodegron. The consensus sequence for this motif is
DpSGXX(X)pS, in which either of the phosphorylated serine res-
idues can be replaced by glutamic or aspartic acid (Frescas and
Pagano, 2008). GBF1 contains three putative phosphodegrons
(Figure 1A). To identify the region of GBF1 required for bTrCP
binding, we made mutants for each of these putative phospho-
degrons, in which the serine and/or glutamic acid residues are
replaced by alanine. Immunoprecipitation experiments showed
that wild-type GBF1 and the two mutants GBF1(S1300A/
S1304A) and GBF1(E1481A/S1486A) bind endogenous bTrCP,
whereas the GBF1(S292A/S297A) mutant does not (Figure 1B).
These results demonstrate that Ser292 and Ser297 are required
for recognition of GBF1 by bTrCP, most likely throughout evolu-
tion, as the phosphodegron is highly conserved in vertebrates
(Figure S2A).
To gain additional insight into the phosphorylation of GBF1 on
Ser292 and Ser297, we generated a phospho-specific antibody3382 Cell Reports 23, 3381–3391, June 12, 2018raised against a peptide containing the two phosphorylated
serine residues. This antibody detects wild-type GBF1, but
not the GBF1(S292A/S297A) mutant (Figure S2B). Moreover,
l-phosphatase treatment of immunoprecipitated wild-type
GBF1 inhibited the detection of GBF1 by the phospho-specific
antibody (Figure S2B). We employed the phospho-specific
Ser292/Ser297 antibody to pinpoint when and where in the cell
GBF1 is phosphorylated. Using synchronized HeLa cells, the
phosphorylation of GBF1 on Ser292/Ser297 was observed
exclusively in mitosis, as monitored by immunoblotting for cell-
cycle markers (Figure 1C). Moreover, GBF1 phosphorylated on
Ser292/Ser297 accumulates in mitotic cells in which the expres-
sion of both bTrCP1 and bTrCP2 was silenced by RNA interfer-
ence (Figure S2C). Accordingly, the interaction of GBF1 with
bTrCP is increased in mitotic cells when compared to that
observed in asynchronous cells (Figure 1D).
The whole-cell abundance of GBF1 did not show a dramatic
decrease in mitotic cells suggesting that only a fraction of
GBF1 is phosphorylated and then degraded. We then carried
out indirect immunofluorescence analysis using the phospho-
specific Ser292/Ser297 antibody. While we did not detect any
endogenous phospho-GBF1 signal in interphase HeLa cells, a
weak phospho-GBF1 signal was observed in late anaphase
and in telophase at the cytoplasmic bridge that forms between
the two daughter cells as the cleavage furrow ingresses (Figures
1E and 1F). The phospho-GBF1 signal at the bridge was not
present in cells in which GBF1 expression was silenced by
RNAi, validating the specificity of our immunostaining (Figures
S2D–S2F).
Next, we analyzed the abundance of GBF1 phosphorylated on
Ser292/Ser297 in cells in which the expression of both bTrCP1
and bTrCP2 was silenced by RNA interference. As shown in Fig-
ures 2A–2D, bTrCP RNAi resulted in increased levels of GBF1
phosphorylated on Ser292/Ser297 at the intercellular bridge in
telophase. In interphase cells (Figure 2A, left panels) and in early
mitosis (Figures S2G–S2I), depletion of bTrCP expression did
not have any detectable effect on the abundance of GBF1
phosphorylated on Ser292/Ser297. These results suggest that
SCFbTrCP is responsible for the degradation of GBF1 phosphor-
ylated on Ser292/Ser297 at the intercellular bridge in latemitosis.
Interestingly, bTrCP-depleted cells in telophase display longer
intercellular bridges when compared to control cells (Figure 2A,
right panels). The phospho-GBF1 signal was not present at the
intercellular cytokinetic bridge in cells in which both bTrCP and
GBF1 were knocked down by RNAi (Figures S2J and S2K)
providing further evidence of the specificity of the phospho-
GBF1 staining at the intercellular bridge. As a complementary
approach, we analyzed the phosphorylation of GBF1 on
Ser292 and Ser297 after overexpression of a dominant-negative
bTrCP mutant (bTrCP1-DF). As shown in Figures 2E and 2F,
ectopic expression of bTrCP1-DF induces the accumulation of
phosphorylated GBF1 at the cytokinetic bridge.
The immunofluorescence results shown in Figures 2A–2C indi-
cate that the pool of phosphorylated GBF1 that is stabilized by
the knockdown of bTrCP colocalizes with the antiparallel arrays
of microtubules present in the intercellular bridge. Accordingly,
GBF1 (detected by an anti-GBF1 antibody) also accumulates
at the intercellular bridge and colocalizes with microtubules in
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Figure 1. GBF1 Is Phosphorylated on
Ser292/Ser297 in Late Mitosis
(A) Schematic representation of the GBF1 protein
with the indicated domains and putative phospho-
degron sequences. DCB, dimerization and cyclo-
philin-binding; HUS, homology upstream of Sec7;
PPB, phosphatidylinositol-phosphate binding;
Sec7, full-length Sec7; Sec7_N, Sec7 N-terminal.
(B) GBF1 Ser292 and Ser297 are required for
GBF1 binding to bTrCP. HEK293T cells were
transfected with an empty vector (EV), HA-tagged
GBF1 wild-type (WT), or the indicated GBF1 mu-
tants. Whole cell extracts were used in anti-HA
immunoprecipitation, after which the binding to
endogenous bTrCP1 was analyzed by immuno-
blotting.
(C) GBF1 is phosphorylated on Ser292/Ser297 in
mitosis. HeLa cells were synchronized at G1/S by
treatment with 2 mM thymidine for 24 hr. Cells
were then washed extensively and incubated in
fresh medium (indicated as time 0) to allow pro-
gression toward mitosis. Cells were harvested at
the indicated time points, lysed and analyzed by
immunoblotting with antibodies for the indicated
proteins.
(D) Increased GBF1-bTrCP interaction in mitotic
cells. Asynchronously growing (AS) or mitotic (M)
cells expressing HA-tagged wild-type GBF1 were
lysed. Whole cell extracts were subjected to direct
immunoblotting with the indicated antibodies or
immunoprecipitation with anti-HA resin followed
by immunoblotting.
(E) GBF1 phosphorylation on Ser292 and Ser297
is detected in late anaphase and telophase. HeLa
cells were fixed and stained with DAPI and anti-
bodies specific for a-tubulin (green) and phospho-
GBF1 (Ser292/Ser297) (red). Scale bars, 10 mm.
(F) The graph shows the percentage of cells that
were either phospho-GBF1 (Ser292/Ser297)-posi-
tive or -negative in the indicated cell-cycle stage.
Early telophase: n = 130; late telophase: n = 120.
See also Figure S1.cells in which the expression of bTrCP was knocked down by
RNAi (Figures 2G and 2H).
CK2-Mediated Phosphorylation of GBF1 on Ser292 and
Ser297
To identify the protein kinase that phosphorylates GBF1 on
Ser292 and Ser297 triggering its degradation, we tested the abil-
ity of a number of recombinant purified kinases to phosphorylate
GBF1 and, more specifically, the GBF1 degron in vitro. We
focused on kinases, namely PLK1, Aurora B, CDK1/cyclin B,
and CK2, which have been shown to localize to the central spin-
dle or the cytokinetic bridge and/or have been previously impli-
cated in the degradation of bTrCP substrates (Frescas and Pa-
gano, 2008; Skop et al., 2004). We found that both CK2 and
CDK1/cyclin B are able to phosphorylate GBF1 (Figure 3A), how-
ever, only CK2 phosphorylates GBF1 on Ser292 and Ser297 as
shown by immunoblotting with the phospho-specific antibody
(Figure 3B). Preincubation of purified GBF1 with CDK1/cyclin B
enhanced the CK2-mediated phosphorylation of GBF1 on
Ser292 and Ser297 in vitro (Figure 3C). Accordingly, selectivepharmacological inhibition of CK2 and CDK1 prevented the
interaction of GBF1 with bTrCP (Figure 3D) as well as the phos-
phorylation of GBF1 on Ser292 and Ser297 at the intercellular
bridge (Figures 3E and 3F). Of note, a number of TBB-treated
cells in telophase exhibited elongated intercellular bridges
when compared to control cells (see below). To exclude nonspe-
cific effects of TBB, we silenced the expression of CK2 by RNAi.
As shown in Figures 3G–3I, the knockdown of CK2 inhibited the
phosphorylation of GBF1 at the intercellular bridge. Finally,
ectopically expressed GBF1 interacts with endogenous CK2a
in cultured cells (Figure 3J).
Collectively, these results suggest a model in which CDK1/cy-
clin B phosphorylates GBF1, thus stimulating the CK2-mediated
phosphorylation of GBF1 on Ser292 and Ser297 and the interac-
tion of GBF1 with bTrCP.
GBF1 Degradation Controls Golgi Membrane
Positioning in Late Mitosis
In telophase, the Golgi apparatus is reassembled at a membrane
cluster next to the midbody as well as at a second cluster nearCell Reports 23, 3381–3391, June 12, 2018 3383
AB E F
C
D
H
G
Figure 2. bTrCP-Dependent Degradation of
Phosphorylated GBF1 in Telophase
(A–D) bTrCP-mediated degradation of phosphory-
lated GBF1 in telophase. HeLa cells were trans-
fected with the indicated siRNA oligonucleotides.
Forty-eight hours after transfection, cells were
either fixed and stained with DAPI and antibodies
specific for phospho-GBF1 (Ser292/Ser297) (red)
and a-tubulin (green) (A–C) or lysed and analyzed
by immunoblottingwith antibodies for the indicated
proteins (D). Scale bars represent 10 mm. The graph
in (B) indicates the percentage of control or bTrCP-
knocked down cells that were phospho-GBF1
(Ser292/Ser297)-positive in the indicated cell-cycle
stage (mean ± SD). *p % 0.01. The graph in (C)
shows the quantification of the phospho-GBF1
(Ser292/Ser297) signal intensity at the intercellular
bridge in control and bTrCP-depleted cells in early
telophase (mean ± SD). *p% 0.01.
(E and F) HeLa cells were transfected with either an
empty vector (EV) or FLAG-tagged bTrCP1(DF-
box) mutant. Forty-eight hours after transfection,
cells were fixed and stained with DAPI and anti-
bodies for HA [bTrCP1(DF-box)] (green) and
phospho-GBF1 (Ser292/Ser297) (red). Scale bars,
10 mm (E). The graph shown in (F) indicates the
percentage of telophase cells, either transfected
with an empty vector (EV) or with HA-epitope
tagged bTrCP-DF, that were phospho-GBF1
(Ser292/Ser297)-positive from two independent
experiments (mean ± SD). *p% 0.01.
(G and H) as in (A) and (B) respectively, except that
cells were stained with DAPI and antibodies spe-
cific for GBF1 (red) and a-tubulin (green).
See also Figure S2.the centrosome at the opposite side of the nucleus (Altan-Bon-
net et al., 2003; Ayala and Colanzi, 2017; Gaietta et al., 2006;
Goss and Toomre, 2008; Jongsma et al., 2015). We tested
whether the phosphorylation-dependent degradation of GBF1
at the intercellular bridge regulates Golgi membrane dynamics
at these two locations.WemonitoredGolgi membrane dynamics3384 Cell Reports 23, 3381–3391, June 12, 2018by time-lapse microscopy in HeLa cells
stably expressing the Golgi stack enzyme
N-acetylgalactosaminyltransferase-2
(GalNAc-T2) fused to GFP (Storrie et al.,
1998) as well as physiological levels
of either wild-type GBF1 or the degra-
dation-resistant GBF1(S292A/S297A)
mutant which accumulates at the inter-
cellular bridge in cytokinesis (Figure S3).
In daughter cells expressing wild-type
GBF1 and in cells transduced with empty
lentiviruses, twin clusters of Golgi mem-
branes form adjacent to the midbody as
well as distal to the midbody (Figures 4
and S4; Video S1). Subsequently, the
Golgi twin proximal to the midbody mi-
grates toward the distal twin eventually
merging into a single Golgi cluster.
Notably, in cells expressing the non-degradable GBF1(S292A/S297A) mutant, the transport of the
midbody-proximal Golgi twin toward the distal Golgi twin is in-
hibited (Figures 4 and S4). Indeed, two Golgi twins are still pre-
sent in each daughter cell at a time when in cells expressing
wild-type GBF1 the proximal Golgi twin has already migrated
to, and coalesced with, the distal twin. Altogether, these results
Figure 3. CK2-Mediated Phosphorylation of GBF1 on Ser292 and
Ser297
(A and B) GBF1 is phosphorylated by CK2 and Cyclin B/CDK1 in vitro. Im-
munopurified GBF1 was dephosphorylated by treatment with l-phosphatase
and then incubated with the indicated purified protein kinases in the presence
of g32P ATP (A) or unlabeled ATP (B). Reactions were stopped by adding
Laemmli buffer, run on SDS-PAGE and analyzed by autoradiography (A, top) or
immunoblotting with antibodies for the indicated proteins (A, bottom, and B).
(C) Stimulation of CK2-dependent phosphorylation of GBF1 (Ser292/Ser297)
by Cyclin B/CDK1 in vitro. Immunopurified GBF1 was first dephosphorylated
by treatment with l-phosphatase and then incubated with the indicated ki-
nases for 20 min. Kinases were then washed away prior to addition of purified
CK2. Reactions were stopped at the indicated times and analyzed by immu-
noblotting.
(D) HeLa cells expressing HA-epitope tagged GBF1 were synchronized in
mitosis and treated with the indicated kinase inhibitors for 2 hr. Cells were then
harvested and lysed. Whole cell extracts were immunoprecipitated (IP) withindicate that the bTrCP-dependent degradation of GBF1 is
required to position the reassembling midbody-proximal Golgi
away from the midbody and toward the distal Golgi ribbon.
GBF1 Degradation Is Required for Golgi Reassembly
The defective movement of the proximal Golgi twin and its
inability to coalesce with the distal Golgi twin in late mitosis in
cells expressing the non-degradable GBF1 mutant suggests
that Golgi reassembly does not occur properly when GBF1
degradation is inhibited. Indeed, postmitotic cells expressing
the degradation-resistant GBF1 mutant display several sepa-
rated Golgi clusters at a time when cells expressing wild-type
GBF1 have already a single coalesced Golgi ribbon (Figure 4B;
compare top panels [GBF1] at 3:29 hr with bottom panels
[non-degradable GBF1 mutant] at 3:29 hr).
Next, we examined the effect of inhibiting the bTrCP-depen-
dent proteolysis of GBF1 on the morphology of the Golgi appa-
ratus in interphase HeLa cells that were fixed and analyzed by in-
direct immunofluorescence using an antibody specific for the
Golgi marker GM130. Whereas expression of physiological
levels of wild-type GBF1 has no significant effects on the
morphology of the Golgi, which forms a typical perinuclear rib-
bon-like structure made of contiguous and interconnected Golgi
stacks, expression of the degradation-resistant GBF1mutant re-
sulted in a disorganized and disassembled Golgi that is not
positioned around the nucleus (Figures 5A, 5B and S5A). Inter-
estingly, expression of a GBF1 phosphomimic mutant, in
which Ser292 and Ser297 are replaced by aspartic acid
(GBF1(S292D/S297D)), also has an effect on Golgi morphology
in interphase cells. Indeed, cells expressing GBF1(S292D/
S297D) display a Golgi apparatus, which, although positioned
perinuclearly (as in control cells), is made of fragmented clusters
that are not connected to form a contiguous narrow ribbonanti-HA resin and analyzed by immunoblotting with antibodies specific for the
indicated proteins.
(E and F) CK2-dependent phosphorylation of GBF1 (Ser292/Ser297) in cells.
HeLa cells were synchronized in mitosis and treated with either DMSO or TBB
for 2 hr. Cells were then fixed and analyzed by immunofluorescence with an-
tibodies specific for a-tubulin (green) and phospho-GBF1 (Ser292/Ser297)
(red) and DAPI (blue). Scale bars, 10 mm. Note that TBB treatment of mitotic
cells results in the formation of elongated cytokinetic bridges (Figures S6E and
S6F). Here, for the sake of clarity, the intensity of the phospho-GBF1 signal
present at bridges of similar length in early telophase cells (chromosomes still
condensed) is shown (E). The graph (F) indicates the percentage of control and
TBB-treated telophase cells that were phospho-GBF1 (Ser292/Ser297)-pos-
itive (mean ± SD). *p% 0.01.
(G–I) CK2-dependent phosphorylation of GBF1 (Ser292/Ser297) in cells. HeLa
cells were treated with the indicated siRNA oligonucleotides. After 48 hr, cells
were synchronized, and either fixed and stained with DAPI and antibodies
specific for phospho-GBF1 (Ser292/Ser297) (red) and a-tubulin (green) (G and
H) or lysed and analyzed by immunoblotting (I). Scale bars, 10 mm. The graph
shown in (H) indicates the percentage of control and CK2-knocked down
telophase cells that were phospho-GBF1 (Ser292/Ser297)-positive (mean ±
SD). *p% 0.01.
(J) GBF1 interaction with CK2a. HEK293T cells were transfected with HA
epitope-tagged GBF1 or an empty vector. After 48 hr, cells were treated with
MG132 for 5 hr. Cells were lysed and whole cell extracts were subjected to
immunoprecipitation using anti-HA resin before immunoblotting with anti-
bodies for the indicated proteins.
See also Figure S2.
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Figure 4. Failure to Degrade GBF1 Inhibits the Transport of the Midbody-Proximal Golgi Twin away from the Cytokinetic Bridge and toward
the Distal Golgi Twin
(A and B) HeLa cells stably expressing the Golgi stack enzyme N-acetylgalactosaminyltransferase-2 (GalNAc-T2) fused to GFP and either wild-type GBF1 or
GBF1(S292A/S297A) were either analyzed by immunoblotting (A) or filmed (B). Representative phase-contrast and epifluorescence images from the time-lapse
series are shown. Time, hr:min. Scale bars, 10 mm. White triangles indicate Golgi twins.
(C) The graph indicates the percentage of daughter cells displaying a single postmitotic Golgi cluster (mean ± SD). *p% 0.01.
See also Figures S3 and S4 and Video S1.(Figure S5A). Of note, neither the S292A/S297A nor the S292D/
S297D mutations affect the ability of GBF1 to localize to the
Golgi in interphase (Figure S5A) or to form homodimers and ho-
motetramers (Figure S5B and not shown) in agreement with
Ser292 and Ser297 being positioned outside the dimerization
domain (DCB) (Figure 1A).
It has been shown that in cells recovering from Brefeldin A
(BFA) treatment, the Golgi apparatus reforms in a manner similar
to the way that the Golgi reassembles in telophase (Shorter and
Warren, 2002). Indeed, the Golgi apparatus reassembles in con-
trol cells (either cells expressing wild-type GBF1 or transduced
with an empty virus) upon BFAwashout. However, cells express-
ing GBF1(S292A/S297A) failed to reform a ribbon-shaped Golgi
apparatus (Figures 5C and 5D).
Although through amechanismdifferent fromBFA, nocodazole
treatment also induces Golgi disassembly. Thus, nocodazole
washout assay provides an additional way to study the molecular
requirements for Golgi assembly. As shown in Figures 5E and 5F,
cells expressing the non-degradable GBF1 mutant do not reform
a ribbon-shaped Golgi apparatus upon nocodazole washout.
GBF1 Proteolysis Is Not Required for Golgi Disassembly
in Early Mitosis
In cells expressing the degradation-resistant GBF1 mutant,
the Golgi apparatus undergoes normal disassembly upon3386 Cell Reports 23, 3381–3391, June 12, 2018BFA or nocodazole treatment (Figures 5C and 5E, left panels).
We then tested whether GBF1 destruction is required for
Golgi disassembly in early mitosis. To this end, we examined
whether timely mitotic dispersion of the Golgi marker GM130
occurs in HeLa cells expressing GBF1(S292A/S297A). All
metaphase cells expressing the degradation-resistant
GBF1 mutant analyzed (n = 60) showed a disassembled
Golgi apparatus (Figures 6A and 6B). In a complementary
approach, we examined the fate of the Golgi apparatus by
time-lapse microscopy in HeLa cells stably expressing the
Golgi stack enzyme N-acetylgalactosaminyltransferase-2
(GalNAc-T2) fused to GFP and either wild-type GBF1 or
the GBF1(S292A/S297A) mutant. Complete Golgi dispersal
occurred in mitotic cells (n = 100) expressing the non-degrad-
able GBF1 mutant (Figures 6C and 6D; Video S2). Altogether,
these results indicate that the CK2/bTrCP-mediated proteoly-
sis of GBF1 is not required for Golgi disassembly in early
mitosis.
GBF1 Stabilization Leads to Cytokinesis Failure
During the phenotypic characterization of cells expressing the
non-degradable GBF1(S292A/S297A) mutant, we noticed an
increased incidence of binucleated and multinucleated cells
compared to cells expressing wild-type GBF1 (Figures 7A–7D)
suggesting cytokinesis failure. To determine at which stage
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Figure 5. GBF1 Degradation Is Required for
Post-mitotic Golgi Reassembly
(A and B) HeLa cells either transduced with an
empty lentivirus (EV) or lentiviruses expressing
wild-type GBF1 or GBF1(S292A/S297A) were
fixed and analyzed by immunofluorescence with
antibodies specific for the Golgi marker GM130
(green) and DAPI (blue) (A). The graph (B) indicates
the percentage of cells with normal Golgi archi-
tecture, i.e., forming a juxtanuclear ribbon (mean ±
SD). *p% 0.01.
(C and D) As in (A) and (B) except that cells were
treated with Brefeldin A (BFA) for 10 min. Cells
were then rinsed (to wash BFA off) and incubated
in fresh media for 2 hr before fixation. Scale bars,
10 mm (C). The graph (D) indicates the percentage
of daughter cells with a reassembled Golgi appa-
ratus (mean ± SD). *p% 0.01.
(E and F) As in (C) and (D) except that nocodazole
treatment (90 min) was used to induce Golgi
fragmentation (E). The graph (F) indicates the
percentage of cells with a reassembled Golgi
apparatus (mean ± SD). *p% 0.01.of cytokinesis GBF1 degradation is required, we analyzed
cell division by time-lapse microscopy. Upon expression of
GBF1(S292A/S297A), the intercellular bridge destabilized before
the end of cytokinesis, resulting in the formation of binucleated
cells (Figures 7E, 7F, S6A, and S6B; Videos S3 and S4). More-Cell Reover, in those cells expressing the GBF1
(S292A/S297A) mutant in which the cyto-
kinetic bridge did not destabilize, delayed
abscission caused the appearance of
elongated intercellular bridges (Figures
7G, 7H, S6C, and S6D). Elongated inter-
cellular bridges were observed also in
cells treated with TBB (Figures S6E and
S6F), which inhibits the CK2-dependent
phosphorylation of the GBF1 degron (Fig-
ures 3D–3F). Taken together, these re-
sults indicate that GBF1 degradation is
required for the post-furrowing steps of
cytokinesis including intercellular bridge
stability and abscission.
To gain additional insights into the mech-
anism by which GBF1 stabilization leads
to cytokinesis failure, we expressed in
HeLa cells a non-degradable GBF1
mutant in which Glu794, a residue critical
for GBF1 nucleotide exchange reaction,
is replaced by lysine. Indeed, it has
been shown that the E794K mutation
abolishes the GEF activity of GBF1 (Gar-
cı´a-Mata et al., 2003) by a well-defined
mechanism (Be´raud-Dufour et al., 1998).
Expression of the GBF1(S292A/S297A/
E794K) mutant in cells resulted in the
accumulation of elongated intercellular
bridges (Figures S6G–S6I) suggestingthat the observed phenotype is independent of GBF1 nucleotide
exchange activity.
To examine whether impaired Golgi reassembly may result in
cytokinesis failure, we treated HeLa cells with BFA and moni-
tored cell division by live cell imaging. As shown in Figure S7ports 23, 3381–3391, June 12, 2018 3387
Figure 6. GBF1 Degradation Is Not Required
for Golgi Disassembly in Early Mitosis
(A and B) HeLa cells expressing either wild-type
GBF1 or GBF1(S292A/S297A) were fixed and
analyzed by immunofluorescence with antibodies
specific for the Golgi marker GM130 (green) and
DAPI (blue). Scale bars, 10 mm. White arrows indi-
cate mitotic cells (A). The graph in (B) indicates the
percentage ofmetaphase cells with dispersedGolgi.
(C and D) HeLa cells stably expressing the Golgi
stack enzyme N-acetylgalactosaminyltransferase-
2 (GalNAc-T2) fused to GFP and either wild-type
GBF1 or GBF1(S292A/S297A) were filmed. Repre-
sentative phase-contrast and epifluorescence im-
ages from the time-lapse series are shown. Time,
hr:min. Scale bars, 10 mm. White arrows indicate
mitotic cells (C). The graph in (D) indicates the
percentage of metaphase cells with dispersed
Golgi.
See also Video S2.and Video S5, cells treated with BFA normally round up in pro-
phase/metaphase, elongate, and display furrow ingression in
anaphase. However, the final stages of cytokinesis are inhibited
and daughter cells fail to separate.
DISCUSSION
Our results uncover a mechanistic basis underlying the striking
changes in Golgi architecture occurring during cell division. We
have shown that a microtubule-localized pool of GBF1 is phos-
phorylated and targeted for degradation at the intercellular cyto-
kinetic bridge. Stabilization of this pool of GBF1 inhibits the trans-
port of theGolgi cluster adjacent to themidbody toward theGolgi
twin positioned next to the centrosome resulting in defective
Golgi reassembly. These findings suggest that GBF1 must be
rapidly degraded to allow for the migration of the midbody-prox-
imal Golgi element along microtubules and its coalescence with
the centrosomal Golgi cluster to reconstitute a properly reas-
sembled andperinuclearly positionedGolgi ribbon.Many studies
have reported that multiple members of the dynein, kinesin, and
myosin motor protein families control the structure and function
of the Golgi apparatus (reviewed in Allan et al., 2002). These re-
ports suggest a possible role of microtubule molecular motors
in the Golgi reassembly and positioning processes controlled
by the bTrCP- and CK2-dependent degradation of GBF1 at
mitotic exit. In this regard, inhibition of cytoplasmic dynein 1 func-
tion results in a Golgi phenotype similar to the one caused by
expression of the non-degradable GBF1 mutant (Allan et al.,
2002). Interestingly, recent studies have shown that GBF1
controls the homeostasis and dynamics of other cellular organ-
elles such as mitochondria (Ackema et al., 2014), endosomes3388 Cell Reports 23, 3381–3391, June 12, 2018(Ackema et al., 2013), and lipid droplets
(Bouvet et al., 2013). It would be compel-
ling to examine whether GBF1 degrada-
tion during mitosis is required for the
transport of other organelles (besides the
Golgi) during late mitosis.The importance of the timely destruction of GBF1 in telo-
phase is revealed by the evidence that inhibition of GBF1
degradation and the resulting defective postmitotic Golgi re-
assembly lead to failure in the terminal phase of cytokinesis.
Indeed, expression of the non-degradable GBF1 mutant re-
sults in cytokinetic bridge instability or persistent connection
between the two daughter cells. Treatment of cells with
BFA, which inhibits GBF1 function, also blocks postmitotic
Golgi reassembly and results in a similar phenotype (Figures
S7A and S7B; Video S5). Taken together, these results sug-
gest that there is a program of GBF1 function and destruction
at the site of cell separation that is required for accurate traf-
ficking of Golgi membranes and positioning of the emerging
Golgi cluster twins during abscission. This choreography of
Golgi elements, assured by the regulation of GBF1 levels,
may be required to ensure precise temporal and spatial regu-
lation of secretion toward the midbody and for membrane
addition to the intercellular bridge during the final steps of
cell separation. Indeed, the stability of the intercellular bridge
as well as the abscission phase of cytokinesis, which are both
defective in cells expressing the degradation-resistant GBF1
mutant, require targeted membrane insertion close to the mid-
body and the formation of specific protein and lipid domains
within the intercellular bridge (Schweitzer and D’Souza-
Schorey, 2004). Intriguingly, it has been recently shown that
GBF1 binds the phosphatidylinositol 4,5-bis phosphate
(PIP2) lipid (Meissner et al., 2018), which is markedly enriched
at the intercellular bridge during late cytokinesis and whose
localization at the bridge is required for both bridge stability
and successful cytokinesis in mammalian cells (Emoto et al.,
2005; Kouranti et al., 2006).
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Figure 7. Inhibition of GBF1 Degradation
Leads to Cytokinetic Bridge Instability and
Cytokinesis Failure
(A and B) HCT116 cells expressing inducible wild-
type GBF1 or GBF1(S292A/S297A) were fixed and
analyzed by immunofluorescence with antibodies
specific for a-tubulin (green) and DAPI (blue). Scale
bars, 50 mm (A). The graph in (B) indicates the
percentage of multinucleated cells.
(C and D) HeLa cells stably expressing the Golgi
stack enzyme N-acetylgalactosaminyltransfer-
ase-2 (GalNAc-T2) fused to GFP and either
wild-type GBF1 or GBF1(S292A/S297A). Scale
bars, 10 mm (C). The graph in (D) indicates the
percentage of multinucleated cells (mean ± SD).
*p % 0.01.
(E and F) HeLa cells expressing wild-type GBF1 or
the GBF1(S292A/S297A) mutant were imaged by
time-lapse phase-contrast microscopy. Repre-
sentative phase-contrast images from the time-
lapse series are shown. Time, hr:min. Scale bars,
10 mm (E). The graph (F) indicates the percentage
of dividing cells that failed cytokinesis (mean ±
SD). *p % 0.01.
(G and H) HeLa cells expressing wild-type GBF1
or GBF1(S292A/S297A) were fixed and analyzed
by immunofluorescence with antibodies specific
for a-tubulin (green) and DAPI (blue). Scale bars,
10 mm (G). The graph (H) indicates the percent-
age of dividing cells with an abnormal cytoki-
netic bridge (mean ± SD). *p % 0.01.
See also Figures S5 and S6 and Videos S3, S4,
and S5.We have shown that the destruction of GBF1 depends on
the phosphorylation of Ser292 and Ser297 by CK2, which
generates a phosphodegron that can be recognized and
bound by bTrCP. We have also found that the CK2-dependent
phosphorylation of the GBF1 degron is stimulated by Cyclin
B/CDK1 in vitro. As CK2 is an acidophilic kinase, CDK1-
dependent phosphorylation of GBF1 might generate an acidic
environment stimulating degron phosphorylation by CK2.
Interestingly, the Lowe group has demonstrated that GBF1
is phosphorylated by Cyclin B/CDK1 in mitosis and shown
that this phosphorylation leads to GBF1 dissociation from
the Golgi membrane (Morohashi et al., 2010). Thus, in early
mitosis, the CDK1-dependent phosphorylation of GBF1 might
facilitate GBF1 degradation by at least two ways, i.e., by pro-Cell Rmoting the dissociation of GBF1 from
Golgi membranes as well as by gener-
ating the negative charges that trigger
the phosphorylation of the GBF1 degron
by CK2.
The evidence that CDK1 (a kinase
highly active in mitosis) phosphorylates
GBF1 (Morohashi et al., 2010) and pro-
motes CK2-mediated degradation of the
GBF1 degron in vitro (Figure 3C) may
explain how GBF1 is targeted for degra-dation specifically in mitosis. However, further studies will be
required to fully understand the temporal and spatial regulation
of GBF1 degradation and, in particular, to uncover how GBF1
is destabilized at the cytokinetic bridge in late mitosis after
CDK1 has been inactivated. In this regard, CK2, which phos-
phorylates GBF1 on the bTrCP-binding domain, has been shown
to localize to the midbody in cytokinesis (Salvi et al., 2014; Sgro`
et al., 2016; Skop et al., 2004).
In conclusion, our work provides mechanistic insights into the
mitotic regulation of Golgi motility and impacts our understand-
ing of the postmitotic reassembly of the Golgi apparatus whose
architecture is essential for fundamental processes such as
secretion, cell migration, formation of immunological synapses
and axon determination.eports 23, 3381–3391, June 12, 2018 3389
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Antibodies
Mouse Monoclonal anti-GBF1 BD Biosciences CAT#612116
Mouse monoclonal anti-p27 BD Biosciences CAT#610242
Mouse monoclonal anti-FLAG Sigma-Aldrich CAT#F3165
Mouse monoclonal anti-a-tubulin FITC-conjugated Sigma-Aldrich CAT#F2168
Mouse Monoclonal anti-HA Covance CAT#MMS-101R
Mouse monoclonal a-tubulin Calbiochem CAT#CP06
Rabbit polyclonal anti-bTrCP1 Cell Signaling Technology CAT#4394
Rabbit polyclonal anti-phospho-histone H3 (Ser10) Merck Millipore CAT#06570
Rabbit polyclonal anti-phospho-GBF1 (Ser292/Ser297) Eurogentec N/A
Rabbit polyclonal anti-FLAG Sigma-Aldrich CAT#F7425
Rabbit polyclonal anti-actin Bethyl Laboratories CAT#A300-491A
Rabbit polyclonal anti-cyclin A Santa Cruz Biotechnology CAT#sc-751
Rabbit polyclonal anti-HA Cell Signaling Technology CAT#3724
Rabbit polyclonal anti-CK2a Santa Cruz Biotechnology CAT#sc-6479
Rabbit polyclonal anti-CUL1 Santa Cruz Biotechnology CAT#sc-11384
Mouse monoclonal anti-GM130 BD Biosciences CAT#610822
Mouse monoclonal anti-Myc Sigma-Aldrich CAT#M5546
Chemicals, Peptides, and Recombinant Proteins
Proteasome Inhibitor MG132 Peptide Institute CAT#3175-v
TBB Casein Kinase II inhibitor Merck Millipore CAT#218697
CDK1 inhibitor IV, RO-3306 Merck Millipore CAT#217699
Brefeldin A Sigma-Aldrich CAT#B6542
Nocodazole Sigma-Aldrich CAT#M1404
Thymidine Sigma-Aldrich CAT#T1895
Tetracycline hydrochloride Sigma-Aldrich CAT#T7660
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Human HeLa ATCC CAT#CCL-2
Human HEK293T ATCC CAT#CRL-11268G-1
Human HCT116 ATCC CAT#CCL-247
Human HeLa-GalNac-T2-GFP N/A N/A
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GBF1 cloning primers Integrated DNA Technologies N/A
ON-TARGET plus HumanGBF1 (8729) siRNA-SMARTpool 5 nmol Dharmacon L-019783-00-0005
GBF1 site-directed mutagenesis primers for degron mutant 50-TC
TACAGACGCTGGCCTGGAATTCGC CTCCCAAACC-3 50-GG
TTTG GGAGGCGAATTCCAGGCC AGCGTCTGTAGA-30
Integrated DNA Technologies N/A
Human bTrCP1/2 siRNA targeting sequence Dharmacon LMRA-000001
Human CK2 siRNA targeting sequence Dharmacon LMRD-000001
Human CK2A10 siRNA targeting sequence Dharmacon LMRD-000003
Recombinant DNA
pcDNA3-GBF1-HA This paper N/A
pHAGE2-pEF1a-GBF1-HA This paper N/A
pHAGE2-pEF1a-GBF1(S292A/S297A)-HA This paper N/A
pcDNA3-GBF1(S292A/S297A)-HA This paper N/A
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pcDNA3-FLAG-FLAG-HA-HA-bTrCP2 D’Annibale et al., 2014 N/A
pcDNA3-FLAG-FLAG-HA-HA-bTrCP2(R447A) D’Annibale et al., 2014 N/A
pcDNA4/TO-GBF1-HA This paper N/A
pcDNA4/TO-GBF1(S292A/S297A)-HA This paper N/A
Critical Commercial Assays
QuickChange Site-Directed Mutagenesis Kit Stratagene Cat#200518
Software and Algorithms
ImageJ https://imagej.nih.gov/ij/ https://imagej.nih.gov/ij/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Dan-
iele Guardavaccaro (d.guardavaccaro@hubrecht.eu).
EXPERIMENTAL MODELS AND SUBJECT DETAILS
HEK293T, HeLa and HCT116 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies) containing
10% fetal calf serum, 100 U /ml penicillin, and 100 mg/ml streptomycin. HCT116 and HeLa cells were treated with doxycycline
(1 mg/ml) to induce the expression of wild-type GBF1 and the GBF1 mutants. The following drugs were used: MG132 (Peptide Insti-
tute; 10 mM), TBB (Merck Millipore, 75 mM), RO-3306 (Merck Millipore, 10 mM), BFA (Sigma-Aldrich, 10 mg/ml), nocodazole (Sigma-
Aldrich, 0.1 mg/ml). For synchronization in mitosis, HeLa cells were first synchronized at G1/S by treatment with 2 mM thymidine for
24 hr. Cells were then washed extensively and incubated in fresh medium to allow progression toward mitosis
METHOD DETAILS
Biochemical methods
For preparation of cell extracts, cells were washed and collected in ice-cold PBS and lysed in lysis buffer (50mMTris pH 7.5, 250mM
NaCl, 0.1% Triton X-100, 1 mM EDTA, 50 mM NaF and protease and phosphatase inhibitors) for 30 min on ice, followed by 20 min
centrifugation at 4C. Cell extracts were then submitted to either immunoblotting or immunoprecipitation followed by immunoblot-
ting. For immunoprecipitation, cell extracts were first incubated with protein G- or protein A-Sepharose beads for 1 hr at 4C for
pre-cleaning and then with the indicated antibody for 3 hr at 4C. Protein G- or protein A-Sepharose beads were then added and
incubated for 45 min. Beads were washed 4 times with lysis buffer and proteins eluted in 5x Laemmli sample buffer. For immuno-
blotting, proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto PVDF membrane (Milli-
pore), and incubated with the indicated antibodies. Mouse monoclonal antibodies were from BD Biosciences (GBF1, GM130, p27),
Sigma-Aldrich (FLAG, a-tubulin FITC-conjugated) and Covance (HA). Rabbit polyclonal antibodies were fromCell Signaling (bTrCP1,
HA) Millipore [phospho-histone H3(Ser10), a-tubulin], Sigma-Aldrich (FLAG), Bethyl (actin) and Santa Cruz Biotechnology (cyclin A,
CK2a and Skp1). Affinity-purified rabbit IgGs were from Sigma-Aldrich.
Purification of bTrCP2 interactors
HEK293T cells were transfected with pcDNA3-FLAG-HA-bTrCP2 and treated with 10 mMMG132 for 5 hr. Cells were harvested and
subsequently lysed in lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, and 0.5% NP-40 plus protease and phos-
phatase inhibitors]. bTrCP2 was immunopurified with anti-FLAG agarose resin (Sigma-Aldrich). Beads were washed, and proteins
were eluted by competition with FLAG peptide (Sigma-Aldrich). The eluate was then subjected to a second immunopurification
with anti-HA resin (12CA5 monoclonal antibody cross-linked to protein G–Sepharose; Invitrogen) before elution in Laemmli sample
buffer. The final eluate was separated by SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and proteins were visualized by Coo-
massie colloidal blue. Bandswere sliced out from the gels and subjected to in-gel digestion. Gel pieces were then reduced, alkylated,
and digested. For mass spectrometric analysis, peptides recovered from in-gel digestion were separated with a C18 column and
introduced by nano-electrospray into an LTQ Orbitrap XL mass spectrometer (Thermo Fisher). Peak lists were generated from the
MS/MS spectra with MaxQuant, and then searched against the International Protein Index human database with Mascot search en-
gine (Matrix Science). Carbamino-methylation (+57 daltons) was set as fixed modification and protein N-terminal acetylation and
methionine oxidation as variable modifications. Peptide tolerance was set to 7 parts per million (ppm) and fragment ion tolerance
was set to 0.5 daltons, allowing two missed cleavages with trypsin enzyme.Cell Reports 23, 3381–3391.e1–e4, June 12, 2018 e2
Generation of phospho-specific antibodies
To generate the anti-GBF1 phosphospecific antibody (Ser292 and S297), rabbits were immunized with the C-STDpSGLEFpSSQT
phosphopeptide (where pS represents phospho-Ser292 and phospho-Ser297). The rabbit polyclonal antiserum was purified
through a two-step purification process. First, the antiserum was passed through a column containing the unphosphorylated
peptide (C-STDSGLEFSSQT) to remove antibodies that recognize the unphosphorylated peptide. The flow-through was then pu-
rified against the phosphopeptide to isolate antibodies that recognize GBF1 phosphorylated on Ser292 and Ser297. The final
product was dialyzed with phosphate-buffered saline (PBS), concentrated, and tested for phosphopeptide and phosphoprotein
specificity.
Transient transfections and lentivirus-mediated gene transfer
Wild-type GBF1 and GBF1 mutants carrying a C-terminal HA tag were subcloned into pcDNA3 vector. For lentiviral transduction,
wild-type GBF1 and mutants were subcloned into pHAGE2-EF1a-IRES-puromycin vectors (Wilson et al., 2008). For inducible
expression, wild-type GBF1 and mutants were subcloned into pcDNA4/TO or in a lentiviral doxycycline-inducible vector. To
construct the lentiviral inducible GBF1 vectors, the EF1a promoter from pHAGE2-EF1a-IRES-Puromycin GBF1 was removed, the
tight TRE promoter was obtained by PCR from pCW-cas9 plasmid (Addgene #50661) and inserted by InFusion cloning (Clontech).
Subsequently, the IRES-puromycin was removed from the GBF1 cDNA and PGK-rtTA-VP16-2A-puro was placed by Infusion clon-
ing. GBF1 mutants were generated by site-directed mutagenesis (NEB Q5/Strategene). All cDNAs were sequenced. For lentiviral
transduction, HEK293T cells were transfected with the polyethylenimine transfection method. Lentiviruses were produced in
HEK293T cells by five-plasmid cotransfection. Briefly, cells were transfected by polyethylenimine (PEI) transfection with the pHAGE2
vector together with packaging vectors encoding Gag-Pol, Rev, Tat, and the G protein of the vesicular stomatitis virus (VSV). Super-
natants were collected every 24 hr on two consecutive days starting 24 hr after transfection, filtered and transferred to a 10-cm plate
of HeLa cells in the presence of polybrene (4 mg/ml). Themediumwas replacedwith DMEMafter 16 hr. GBF1mutants were generated
by site-directed mutagenesis (Stratagene).
In vitro ubiquitylation assay
GBF1 ubiquitylation was performed in a volume of 10 mL containing SCFbTrCP-GBF1 immunocomplexes, 50 mM Tris (pH 7.6), 5 mM
MgCl2, 0.6 mM dithiothreitol (DTT), 2 mM adenosine triphosphate (ATP), E1 (1.5 ng/ml; Boston Biochem), Ubc3 (10 ng/ml), ubiquitin
(2.5 mg/ml; Sigma-Aldrich), and 1 mM ubiquitin aldehyde. The reactions were incubated at 30C for the indicated times and analyzed
by immunoblotting.
In vitro kinase assay
ImmunopurifiedGBF1was first dephosphorylated by treatment with lambda phosphatase and then incubated at 30C for 30min with
0.2 mM ATP and the indicated kinases in a 20 mL of kinase buffer (25 mM Tris pH 7.5, 10 mM MgCl2, 2 mM DTT, 5 mM b-glycero-
phosphate, 0.1 mM sodium orthovanadate). Reaction products were subjected to immunoblotting. Autoradiography was performed
when g32P ATP was used. For sequential in vitro kinase assay (Figure 3C), immunopurified GBF1 was subjected to a first phosphor-
ylation reaction (30min) with the indicated purified kinases. Samples were then washed three times in lysis buffer (50mMTris-HCl pH
7.5, 250 mM NaCl, 0.1% Triton X-100, 1 mM EGTA) to remove the first kinase and twice in kinase buffer. Samples were then sub-
jected to a second phosphorylation reaction with CK2 as described above.
Live cell imaging
Time-lapse imaging of GalNAc-T2-GFP HeLa expressing either wild-type GBF1 or the GBF1(S292A/S297A) mutant was conducted
under a Leica TCS SP8 laser scanning confocal microscope with excitation of 488nm utilizing HyD detectors. Prior to imaging, cells
were seeded in a 4-compartment glass bottomed cell culture dish (Greiner Bio-One) using Dulbecco’s modified Eagle’s medium
without Phenol Red (DMEM; Life Technologies) containing 10% fetal calf serum, 100 U /ml penicillin, and 100 mg/ml streptomycin.
Cells were imaged every 11-12min for a period of 15-16 hr, in a controlled chamber at 37C and 5%CO2. Image analysis and Z stack
processing was done by using ImageJ software.
Immunofluorescence
Cells were seeded on coverslips coated with polylysine-L (Sigma-Aldrich) in complete medium. Cells were fixed in 4% paraformal-
dehyde, permeabilized with 0.1% Triton X-100 in PBS and then incubated with the primary antibody for 2 hr at room temperature in
10% donkey serum. Cells were washed three times in 0.5% Tween-20 in PBS (TBST) and incubated with secondary antibody for 1 hr
at room temperature. Cells were washed three times with TBST. Slides were mounted using ProLongGold Antifade Mountant with
DAPI (Molecular Probes, Life Technologies).
QUANTIFICATION AND STATISTICAL ANALYSIS
The following criteria were used for quantification: for cytokinetic bridges, elongated bridges were scored when longer
than the diameter of a reforming telophase HeLa cell nucleus (approximately 10 mm); for Golgi morphology, cells withe3 Cell Reports 23, 3381–3391.e1–e4, June 12, 2018
disassembled/fragmented Golgi were scored if containing a Golgi disorganized and fragmented in numerous small non-contig-
uous Golgi patches, whereas cells with (re)assembled Golgi were scored if displaying either a perinuclear ribbon-shape Golgi
or a juxtanuclear single-cluster Golgi.
Sample sizes and p values are indicated in the text, figures or figure legends. p values are derived from unpaired two-tailed t tests.
All images are representative of at least three independent experiments, except where specified in the figure legends.Cell Reports 23, 3381–3391.e1–e4, June 12, 2018 e4
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Figure S1 related to Figure 1. GBF1 interacts with βTrCP, and is ubiquitylated by, the SCFβTrCP 
ubiquitin ligase 
(A) The table indicates the mass spectrometry analysis of wild type βTrCP2 and βTrCP2(R447A) 
immunopurifications. Protein symbol, accession number, molecular weight and number of unique 
peptides recovered for the indicated proteins are shown. 
(B, C) GBF1 interacts specifically with βTrCP. HEK293T cells, transfected with an empty vector (EV) 
or the indicated FLAG-tagged substrate recognition subunits of either SCF or APC/C E3 ligases, were 
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treated with MG132 for 5 hours and lysed. Cell extracts were used for FLAG immunoprecipitations and 
analyzed by immunoblotting.  
(D) Endogenous βTrCP1 is recovered in immunoprecipitated HA epitope-tagged GBF1. HEK293T 
cells were transfected with an empty vector of HA-tagged GBF1. Cells were lysed and whole cell 
extracts were immunoprecipitated with HA resin and analyzed by immunoblotting with anti-βTrCP1 
and HA antibodies. 
(E) The table indicates the mass spectrometry analysis of wild type GBF1 immunopurification. Protein 
symbol, accession number, molecular weight and number of total spectra recovered for the indicated 
proteins are shown. 
(F) A complex of endogenous GBF1 and βTrCP1 is present in HEK293T cells. Cell lysates from 
MG132-treated HEK293T cells were submitted to immunoprecipitation with either affinity-purified 
mouse immunoglobulin G (IgG) or with affinity-purified monoclonal antibody against GBF1. 
Immunocomplexes were then immunoblotted with antibodies for the indicated proteins. 
(G) GBF1 is ubiquitylated by SCFβTrCP in vitro. HEK293T cells were transfected with GBF1, Skp1, 
Cul1, Rbx1, and either FLAG-tagged βTrCP1 or βTrCP1-ΔF-box. In vitro ubiquitylation of GBF1 was 
performed with anti-FLAG immunoprecipitates, which were immunoblotted with an anti-GBF1 
antibody. 
(H) As in G except that immunoprecipitates were immunoblotted with an anti-ubiquitin antibody. 
(I) Ubiquitylation of GBF1 by βTrCP1 in cultured cells. HEK293T cells were transfected with FLAG-
tagged GBF1 and HA-tagged ubiquitin, with or without MYC-tagged βTrCP1. Lysates were prepared in 
denaturing buffer and identical aliquots were immunoprecipitated with antibodies directed against HA. 
Immunoprecipitates were then immunoblotted to detect ubiquitylated GBF1. 
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Figure S2 related to Figure 2. GBF1 phosphorylation on Ser292/Ser297 promotes βTrCP-
mediated degradation of GBF1 in mitosis. Continued on the next page. 
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(A) Alignment of the amino acid regions corresponding to the βTrCP-binding motif (highlighted in 
green) in previously reported βTrCP substrates and GBF1 orthologs. The amino acid sequence of the 
GBF1 phosphodegron mutant is shown at the bottom, with the altered amino acids in blue. 
(B) Characterization of a phospho-specific antibody that detects GBF1 phosphorylated on 
Ser292 and Ser297. Immunoprecipitated wild-type GBF1 and GBF1(S292A/S297A) were 
analyzed by immunoblotting with antibodies specific for the indicated proteins. Where indicated, 
immunocomplexes were treated with lambda phosphatase (lPP) for 30 min. WCE: whole cell 
extracts. 
(C) HeLa cells were transfected with the indicated siRNA oligonucleotides. Twenty-four hours 
after transfection, cells were synchronized at G1/S by treatment with 2 mM thymidine for 24 
hours. Cells were then washed extensively and incubated in fresh medium to allow progression 
toward mitosis. After 10-12 hours (when microscopic evaluation revealed enrichment of dividing 
cells) cells were harvested, lysed and analyzed by immunoblotting with antibodies for the 
indicated proteins. M, mitosis.  
(D-F) Hela cells were transfected with the indicated siRNA oligonucleotides. Forty-eight hours 
after transfection, cells were collected, lysed and analyzed by immunoblotting (D) or fixed and 
stained with DAPI and antibodies specific for a-tubulin (green) and phospho-GBF1 (red) (E). 
Scale bars represent 10 µm. The graph in (F) indicates the percentage of control or GBF1-
knocked down telophase cells that were phospho-GBF1 (Ser292/Ser297) positive (mean ± s.d.). 
* P £ 0.05. 
(G-I) HeLa cells were transfected with the indicated siRNA oligonucleotides. Forty-eight hours after 
transfection, cells were either fixed and stained with DAPI and antibodies specific for phospho-GBF1 
(Ser292/Ser297) (red) and a-tubulin (green). Scale bars represent 10 µm. The graphs indicate the 
quantification of the phospho-GBF1 (Ser292/Ser297) signal intensity in control and βTrCP-depleted 
cells in prometaphase (H) or metaphase (I) (mean ± s.d.). NS, not significant.  
	 5	
(J-K) Hela cells were transfected with the indicated siRNA oligonucleotides and analyzed by 
immunofluorescence as in (E). Scale bars represent 10 µm. The graph in (K) indicates the percentage 
of control, βTrCP-, or βTrCP/GBF1-knocked down cells that were phospho-GBF1 (Ser292/Ser297) 
positive in early or late telophase (mean ± s.d.). * P £ 0.05. 
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Figure S3 related to Figure 4. HeLa cells either transduced with lentiviruses expressing HA-epitope 
tagged wild type GBF1, GBF1(S292A/S297A) or GBF1(S292D/S297D) were fixed and analyzed by 
immunofluorescence with antibodies specific for HA (green), a-tubulin (red) and DAPI (blue). 
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Figure S4 related to Figure 4. Failure to degrade GBF1 inhibits the transport of the midbody-
proximal Golgi twin away from the cytokinetic bridge and towards the distal Golgi twin. 
(A-B) HeLa cells stably expressing the Golgi stack enzyme N-acetylgalactosaminyltransferase-2 
(GalNAc-T2) fused to GFP were transduced with empty viruses (EV) or viruses expressing either wild 
type GBF1 or GBF1(S292A/S297A). Cells were filmed as described in Star Methods. Representative 
phase-contrast and epifluorescence images from the time-lapse series are shown. Time, hr:min. Scale 
bars represent 10 µm. White triangles indicate Golgi twins. The graph in (B) indicates the percentage 
of daughter cells displaying a single compact postmitotic Golgi (mean ± s.d.). * P £ 0.01. NS, not 
significant. 
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Figure S5 related to Figure 4.  
(A) HeLa cells either transduced with lentiviruses expressing HA-tagged wild type GBF1, 
GBF1(S292A/S297A) or  GBF1(S292D/S297D) were fixed and analyzed by 
immunofluorescence with antibodies specific for HA (GBF1 - red), the Golgi marker GM130 
(green) and DAPI (blue). Scale bars represent 8 µm. 
(B) HeLa cells stably expressing HA-tagged wild type GBF1 were transfected with an empty vector 
(EV), FLAG-tagged wild type GBF1 (WT) or FLAG-tagged GBF1(S292A/S297A). Whole cell extracts 
were used in anti-FLAG immunoprecipitation, after which the binding to HA-tagged GBF1 was 
analyzed by immunoblotting. 
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Figure S6 related to Figure 7. Inhibition of GBF1 degradation causes cytokinetic bridge 
instability and cytokinesis failure. Continued on the next page. 
A C
B
D
0
0:10
0:20
GBF1
1:40
0
0:10
0:20
2:40
2:300:40
0:50
GBF1
(S292A/S297A)
5:10
GBF1
a
-T
ub
ul
in
D
AP
I
M
er
ge
GBF1
(S292A/S297A)
E
lo
ng
at
ed
 b
rid
ge
s 
(%
)
0
20
40
60
80 *
GBF1
(S292A/S297A)
GBF1
GBF1
(S292A/S297A)
GBF1
0
5
10
15
20
25
C
yt
ok
in
es
is
 fa
ilu
re
 (%
)
*
a
-T
ub
ul
in
D
AP
I
M
er
ge
TBBDMSO
E
F
0
10
20
30
40
50
60
DMSO TBB
E
lo
ng
at
ed
 b
rid
ge
s 
(%
)
*
H I
G
GBF1 GBF1(S292A/S297A) GBF1(S292A/S297A/E794K)
D
AP
I
M
er
ge
α-
Tu
bu
lin
 
GBF1 
(anti-HA)
GBF1
Actin
- +     - +     - +     TET
GB
F1
(S2
92
A/S
29
7A
)
GB
F1
GB
F1
(S2
92
A/S
29
7A
/E7
94
K)
El
on
ga
te
d 
br
id
ge
s 
(%
)
*
*
0
20
40
60
GB
F1
GB
F1
(S
29
2A
/S
29
7A
)
GB
F1
(S
29
2A
/S
29
7A
/E
79
…
	 10	
(A-B) Time-lapse images of HCT116 cells expressing wild type GBF1 or the GBF1(S292A/S297A) 
mutant. Time, hr:min. Scale bars represent 10 µm. The graph (B) indicates mean percentage of 
dividing cells that failed cytokinesis (mean ± s.d.). * P £ 0.05. 
(C-D) HCT116 cells expressing wild type GBF1 or GBF1(S292A/S297A) were fixed and analyzed by 
immunofluorescence with antibodies specific for a-tubulin (green) and DAPI (blue). Scale bars 
represent 10 µm. The graph (D) indicates the percentage of dividing cells with an abnormal 
intercellular bridge (mean ± s.d.). * P £ 0.05.  
(E-F) HeLa cells were synchronized in mitosis as described in Figure S2C. Cells were treated with 
either DMSO or TBB for 3 hours, fixed, and analyzed by immunofluorescence with antibodies specific 
for a-tubulin (green) and DAPI (blue). Scale bars represent 10 µm. The graph (F) indicates the 
percentage of cells in cytokinesis with an abnormal intercellular bridge (mean ± s.d.). * P £ 0.05.  
(G-I) HeLa cells expressing wild type GBF1, GBF1(S292A/S297A) or GBF1(S292A/S297A/E794K) 
were either analyzed by immunoblotting with the indicated antibodies (G) or by immunofluorescence 
with antibodies specific for a-tubulin (green) and DAPI (blue) (H). Scale bars represent 10 µm. The 
graph (I) indicates the percentage of dividing cells with an abnormal intercellular bridge (mean ± s.d.). 
* P £ 0.05.  
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Figure S7 related to Figure 7. Inhibition of Golgi reassembly leads to cytokinesis failure. 
(A) HeLa cells stably expressing the Golgi stack enzyme N-acetylgalactosaminyltransferase-2 
(GalNAc-T2) fused to GFP were treated with Brefeldin A and filmed. Representative phase-contrast 
and epifluorescence images from the time-lapse series are shown. Time, hr:min. Scale bars represent 
10 µm. White arrows indicate dividing cells. White triangles indicate Golgi twins.  
(B) The graph indicates the percentage of control or BFA-treated dividing cells that failed cytokinesis 
(mean ± s.d.). * P £ 0.001. 
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